Ferrari Jill
The University of East London, London, UK.
BMJ Clin Evid. 2014 Mar 13;2014:1715.
Fungal infections are reported to cause 23% of foot diseases and 50% of nail conditions in people seen by dermatologists, but are less common in the general population, affecting 3% to 12% of people.
We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of oral treatments for fungal toenail infections in adults? What are the effects of topical treatments for fungal toenail infections in adults? We searched: Medline, Embase, The Cochrane Library, and other important databases up to October 2013 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
We found 13 studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
In this systematic review, we present information relating to the effectiveness and safety of the following interventions: amorolfine, butenafine, ciclopirox, fluconazole, itraconazole, terbinafine, tioconazole, and topical ketoconazole.
据报道，在皮肤科医生接诊的患者中，真菌感染导致23%的足部疾病和50%的指甲病症，但在普通人群中较少见，影响3%至12%的人。
我们进行了一项系统评价，旨在回答以下临床问题：成人口服治疗真菌性趾甲感染的效果如何？成人外用治疗真菌性趾甲感染的效果如何？我们检索了：截至2013年10月的医学期刊数据库（Medline）、荷兰医学文摘数据库（Embase）、考克兰图书馆及其他重要数据库（临床证据综述会定期更新；请查看我们的网站获取本综述的最新版本）。我们纳入了来自美国食品药品监督管理局（FDA）和英国药品及医疗保健产品监管局（MHRA）等相关机构的危害警示。
我们发现13项研究符合我们的纳入标准。我们对干预措施的证据质量进行了GRADE评估。
在本系统评价中，我们提供了以下干预措施有效性和安全性的相关信息：阿莫罗芬、布替萘芬、环吡酮、氟康唑、伊曲康唑、特比萘芬、噻康唑和外用酮康唑。
